As Congress begins work on tax legislation, this letter points out the benefits of the 2017 corporate tax rate of 21% for American competitiveness and average Americans.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

 Conservatives asked House leaders to bring up PBM reforms helping patient access to medicines and lower out-of-pocket costs.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

 Conservative leaders offer Trump team ways to win innovation leadership by outcompeting China, the EU and others.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

Blurb:  

The Medication Affordability and Patent Integrity Act is well-intentioned, but would hinder innovation and  expose valuable U.S. trade secrets.

 Conservative leaders voice support to Senators for patent bills. PREVAIL removes bias at PTAB, and PERA cancels judicial exceptions to matter that’s patent-eligible. 

 We urge Congress to protect U.S. national security by shoring up the policy underpinnings that will protect our country’s innovation leadership in key technologies. 

 PERA shifts from the unworkable ‘Alice-Mayo Framework’ to clear standards for determining what’s patent-eligible. 

 This bipartisan, bicameral bill restores access to injunctions in cases where patents are proven infringed. The RESTORE Act corrects a judicially created error of injustice. 

The ITC’s evidence-based process protects U.S. innovators. Congress shouldn’t reward IP infringers and Chinese manufacturers by weakening it.

CPR agrees with bipartisan, former top PTO officials that this must be immediately withdrawn. (If there’s room, include: Its far-reaching lengths are contrary to statute.)

History shows that price controls never achieve their stated ends and the IRA’s price controls are further evidence.

PTO's PTAB reforms won't restore balance to the patent system. It should codify Fintiv and require PTAB to accept a court’s or USITC’s decision that a patent is valid.

Qualifying innovations for FTC examination or enforcement would discourage developing drugs for indications with unmet medical needs, including cancers.

The IRA's 95% excise tax on medicines will be punitive, unworkable, and ultimately indefensible.

Marcum's new study of patent litigation shows that civil litigation now holds less promise of delivering justice to inventors and patent owners.

H.R. 3535 adds hurdles to the U.S. International Trade Commission’s ability to keep IP-infringing products out, enabling infringers to keep supply chains in China.

The Restoring America’s Leadership in Innovation Act would strengthen private intellectual property rights. RALIA would reverse the antipatent onslaught of recent years.

The Sunset Act reins in the Administrative State's rules, regulations, and guidance. They would no longer remain in force in perpetuity.

These excerpt public comments that oppose the Biden draft guidance for Bayh-Dole march-in to forcibly relicense patents if an agency disagrees with the product price.

The proposed guidance would endanger American economic competitiveness, inhibit innovation, impede public private partnerships, and harm U.S. technological leadership in cutting-edge sectors.

NIST proposes the most destructive policy: Injecting pricing into Bayh-Dole march-in, which has never been used and lacks statutory grounds for product price. NIST must withdraw it.

CPR commends Reps. Randy Feenstra (R-IA) and Sanford Bishop (D-GA) on the House Death Tax Repeal Act. It has over 160 original cosponsors, and the supporting coalition letter has nearly 160 signers.

H.R. 6758 enables property owners to hold the federal government accountable for takings. Its more efficient, uniform process secures Fifth Amendment rights.